Department of Molecular and System Pharmacology, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi, Fukuoka 812-8582, Japan.
Exp Neurol. 2012 Apr;234(2):293-301. doi: 10.1016/j.expneurol.2011.09.016. Epub 2011 Sep 17.
We have learned various data on the role of purinoceptors (P2X4, P2X7, P2Y6 and P2Y12) expressed in spinal microglia and several factors that presumably activate microglia in neuropathic pain after peripheral nerve injury. Purinergic receptor-mediated spinal microglial functions make a critical contribution to pathologically enhanced pain processing in the dorsal horn. Microglial purinoceptors might be promising targets for treating neuropathic pain. A predicted therapeutic benefit of interfering with microglial purinergic receptors may be that normal pain sensitivity would be unaffected since expression or activity of most of these receptors are upregulated or enhanced predominantly in activated microglia in the spinal cord where damaged sensory fibers project.
我们已经了解了在脊髓小胶质细胞中表达的嘌呤能受体（P2X4、P2X7、P2Y6 和 P2Y12）以及外周神经损伤后可能激活小胶质细胞的几种因素在神经病理性疼痛中的作用。嘌呤能受体介导的脊髓小胶质细胞功能对背角病理性增强的疼痛处理有重要贡献。小胶质细胞嘌呤能受体可能是治疗神经病理性疼痛的有前途的靶点。干扰小胶质细胞嘌呤能受体可能具有预测性的治疗益处，因为正常的疼痛敏感性不会受到影响，因为这些受体中的大多数在脊髓中受损感觉纤维投射的活化小胶质细胞中主要上调或增强表达或活性。
